Patents by Inventor Katsuki Ohtani
Katsuki Ohtani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180052158Abstract: A method for examining a complement system of a subject, including: a reaction step of letting a scavenger receptor or a functional equivalent thereof, a pentraxin family protein or a functional equivalent thereof and a blood sample collected from the subject coexist in vitro; and a detection step of detecting complement activation amplifying reaction and/or complement activation late-phase reaction induced by interaction between the scavenger receptor or the functional equivalent thereof and the pentraxin family protein or the functional equivalent thereof from a reactant after the reaction step. Also provided are a kit for examining a complement system, and a method for testing a test substance for the ability to activate or suppress a complement system.Type: ApplicationFiled: August 9, 2017Publication date: February 22, 2018Applicant: National University Corporation Asahikawa Medical UniversityInventors: Nobutaka Wakamiya, Katsuki Ohtani
-
Patent number: 8604162Abstract: Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof.Type: GrantFiled: June 14, 2011Date of Patent: December 10, 2013Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Yuichiro Kishi
-
Publication number: 20130150565Abstract: Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof.Type: ApplicationFiled: June 14, 2011Publication date: June 13, 2013Applicant: Fuso Pharmaceutical Industries, Ltd.Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Yuichiro Kishi
-
Patent number: 7985833Abstract: Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof.Type: GrantFiled: December 12, 2008Date of Patent: July 26, 2011Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Nobutaka Wakamiya, Hiroyuki Keshi, Katsuki Ohtani, Takashi Sakamoto, Yuichiro Kishi
-
Publication number: 20090275740Abstract: Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof.Type: ApplicationFiled: December 12, 2008Publication date: November 5, 2009Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nobutaka Wakamiya, Hiroyuki Keshi, Katsuki Ohtani, Takashi Sakamoto, Yuichiro Kishi
-
Publication number: 20090048165Abstract: Disclosed are anti-HIV agents which comprise a mannose binding protein (MBP) as an active component and are useful for effectively inhibiting progress of diseases state in and useful in therapy for individuals infected with human immunodeficiency virus (HIV). Also disclosed are a method for evaluating an anti-HIV activity of MBP comprising the step of culturing HIV infected cells under the presence of MBP.Type: ApplicationFiled: July 8, 2008Publication date: February 19, 2009Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Hiroyuki Keshi, Yuichiro Kishi
-
Publication number: 20070191265Abstract: Disclosed are anti-HIV agents which comprise a mannose binding protein (MBP) as an active component and are useful for effectively inhibiting progress of diseases state in and useful in therapy for individuals infected with human immunodeficiency virus (HIV). Also disclosed are a method for evaluating an anti-HIV activity of MBP comprising the step of culturing HIV infected cells under the presence of MBP.Type: ApplicationFiled: March 27, 2007Publication date: August 16, 2007Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Hiroyuki Keshi, Yuichiro Kishi
-
Publication number: 20070190652Abstract: Disclosed are anti-HIV agents which comprise a mannose binding protein (MBP) as an active component and are useful for effectively inhibiting progress of diseases state in and useful in therapy for individuals infected with human immunodeficiency virus (HIV). Also disclosed are a method for evaluating an anti-HIV activity of MBP comprising the step of culturing HIV infected cells under the presence of MBP.Type: ApplicationFiled: March 27, 2007Publication date: August 16, 2007Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Hiroyuki Keshi, Yuichiro Kishi
-
Publication number: 20070184477Abstract: Disclosed are anti-HIV agents which comprise a mannose binding protein (MBP) as an active component and are useful for effectively inhibiting progress of diseases state in and useful in therapy for individuals infected with human immunodeficiency virus (HIV). Also disclosed are a method for evaluating an anti-HIV activity of MBP comprising the step of culturing HIV infected cells under the presence of MBP.Type: ApplicationFiled: March 27, 2007Publication date: August 9, 2007Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Hiroyuki Keshi, Yuichiro Kishi
-
Publication number: 20050123899Abstract: Disclosed are anti-HIV agents which comprise a mannose binding protein (MBP) as an active component and are useful for effectively inhibiting progress of diseases state in and useful in therapy for individuals infected with human immunodeficiency virus (HIV). Also disclosed are a method for evaluating an anti-HIV activity of MBP comprising the step of culturing HIV infected cells under the presence of MBP.Type: ApplicationFiled: June 30, 2003Publication date: June 9, 2005Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Hiroyuki Keshi
-
Publication number: 20030158382Abstract: Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof.Type: ApplicationFiled: March 19, 2003Publication date: August 21, 2003Inventors: Nobutaka Wakamiya, Hiroyuki Keshi, Katsuki Ohtani, Takashi Sakamoto, Yuichiro Kishi